The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
Alison M. Schram(Memorial Sloan Kettering Cancer Center), Justin Meyerowitz(Stanford University), Yu Chi Yang(Revolution Medicines (United States)), Susanna V. Ulahannan(Oklahoma State University Oklahoma City), Zhican Wang(Revolution Medicines (United States)), Mallika Singh(Revolution Medicines (United States)), Sumit Kar, Eric B. Haura(Moffitt Cancer Center), Howard A. Burris(Deaconess Hospital), Jonathan W. Riess(University of California Davis Medical Center), W. Clay Gustafson(Revolution Medicines (United States)), Pamela N. Münster(University of California, San Francisco), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Abdul Rafeh Naqash(Oklahoma City University), Robert J. Friedman(New York University), Tao Lin(Revolution Medicines (United States)), Michael L. Cheng(University of California, San Francisco), Vidya Seshadri(Revolution Medicines (United States)), R. D. Penn(Astellas Pharma (China)), Bojena Bitman(Revolution Medicines (United States))
Cited by 7
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k